Karen Prange

Filings by Karen Prange span 7 companies, the busiest being AtriCure, Inc., Embecta Corp. and Nevro Corp. Over a trading history stretching from 1 January 2016 to 5 August 2026, the count stands at 29 filings.

On the open market, the record shows 1 purchase worth €3,277 and 6 sales worth €450k. The amount is not disclosed for 1 filing. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 19 share grants and 1 option exercise. In 2026 alone, the filings show no purchases and 2 sales.

Most recently, on 7 August 2026, the filings show an open-market sale worth €120k in AtriCure, Inc. The last purchase on record was published on 12 May 2022, which is 1,620 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.